BioXcel Therapeutics, Inc. (BTAI) shares rose 4.21 percent to $1.36 on Friday after the company announced the completion of the last patient last visit in its pivotal Phase 3 SERENITY At-Home clinical trial. The trial evaluates BXCL501 for the treatment of agitation associated with bipolar disorders or schizophrenia in an at-home setting.
The stock is currently trading at $1.39, up $0.08 from the previous close of $1.31 on the Nasdaq. Shares opened at $1.65 and have ranged between $1.34 and $2.07 so far today. Volume has surged to 102.7 million, far above the average daily volume of 344,000. The stock has traded between $1.17 and $16.72 over the past 52 weeks.
The company expects to release topline data from the study later this month. Results will support a planned supplemental New Drug Application for IGALMI to potentially expand its label for outpatient use.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.